title: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.
abstract: A continuous infusion of vancomycin (CIV) may provide an alternative mode of infusion in severe hospital-acquired methicillin-resistant staphylococcal (MRS) infections. A multicenter, prospective, randomized study was designed to compare CIV (targeted plateau drug serum concentrations of 20 to 25 mg/liter) and intermittent infusions of vancomycin (IIV; targeted trough drug serum concentrations of 10 to 15 mg/liter) in 119 critically ill patients with MRS infections (bacteremic infections, 35%; pneumonia, 45%). Microbiological and clinical outcomes, safety, pharmacokinetics, ease of treatment adjustment, and cost were compared. Microbiological and clinical outcomes and safety were similar. CIV patients reached the targeted concentrations faster (36 +/- 31 versus 51 +/- 39 h, P = 0.029) and fewer samples were required for treatment monitoring than with IIV patients (7.7 +/- 2.2 versus 11.8 +/- 3.9 per treatment, P < 0.0001). The variability between patients in both the area under the serum concentration-time curve (AUC(24h)) and the daily dose given over 10 days of treatment was lower with CIV than with IIV (variances, 14,621 versus 53,975 mg(2)/liter(2)/h(2) [P = 0.026] and 414 versus 818 g(2) [P = 0.057], respectively). The 10-day treatment cost per patient was $454 +/- 137 in the IIV group and was 23% lower in the CIV group ($321 +/- 81: P < 0.0001). In summary, for comparable efficacy and tolerance, CIV may be a cost-effective alternative to IIV.
authors.affiliation: Medico-Surgical Intensive Care Unit, Institut Mutualiste Montsouris, Paris, France. marc.wysocki@imm.fr
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
authors.forename: F
authors.initials: F
authors.lastname: Delatour
authors.forename: F
authors.initials: F
authors.lastname: Faurisson
authors.forename: A
authors.initials: A
authors.lastname: Rauss
authors.forename: Y
authors.initials: Y
authors.lastname: Pean
authors.forename: B
authors.initials: B
authors.lastname: Misset
authors.forename: F
authors.initials: F
authors.lastname: Thomas
authors.forename: J F
authors.initials: JF
authors.lastname: Timsit
authors.forename: T
authors.initials: T
authors.lastname: Similowski
authors.forename: H
authors.initials: H
authors.lastname: Mentec
authors.forename: L
authors.initials: L
authors.lastname: Mier
authors.forename: D
authors.initials: D
authors.lastname: Dreyfuss
mesh_terms: D000328:Adult; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D014640:Vancomycin